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Background: Renal biopsy registries allow histopathological data to be collected to improve
knowledge of different pathologies and their natural history.
Aim: To analyse the data of the Castilla La Mancha Glomerulonephritis Registry (GLOMAN-
CHA) and the evolution of the different biopsy-proven pathologies between 1994 and 2008.
Methods: The 6 most common biopsy-proven pathologies were collected during the 14 years
of  the study (941 biopsies) in the 5 participant centres of the autonomous community. In
2008,  we assessed patient renal survival and mortality and we evaluated associated factors
to  each situation for each pathology.
Results: Of the 941 biopsies, 59% belonged to men, with a mean age of 48 ± 18 years. At the
time  of the biopsy, the median glomerular ﬁltration rate was 50.3 (25.5–76.3) ml/min/1.73 m2
and median proteinuria was 3.4 (1.5–6.4) grams per day. The most common pathology
were lupus nephropathy, followed by focal segmental glomerulosclerosis and membranousnephropathy. Lupus nephropathy and minimal change disease achieved the best renal prog-nosis during follow-up (mean 7.3 ± 4.8 years). Rapidly progressive glomerulonephritis type 3
and focal segmental glomerulosclerosis had the worst renal prognosis. In addition, rapidly
progressive glomerulonephritis type 3 presented the worst vital prognosis.
 Please cite this article as: Conde Olasagasti JL, Acevedo Ribó M, Roca Mun˜oz A, Vozmediano Poyatos C, Rivera F, Illescas Fernández-
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Conclusions: In GLOMANCHA, we demonstrate the poor prognosis of rapidly progressive
glomerulonephritis type 3, in contrast to minimal change disease or lupus nephropathy.
Renal function is an independent predictor of renal survival and mortality in this study.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Estudio  evolutivo  de  las  glomerulonefritis  en  Castilla-La  Mancha
(GLOMANCHA)  en  el  periodo  1994-2008
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Antecedentes: Los registros de biopsias renales permiten la recogida de datos histopatológicos
que, puestos en su conjunto, ayudan a comprender enfermedades y su historia natural.
Objetivos: Analizar los datos del Registro de Glomerulonefritis de Castilla-La Mancha (GLO-
MANCHA) y la evolución de las diferentes enfermedades biopsiadas (1994-2008).
Métodos: Se recogieron las 6 enfermedades biopsiadas más prevalentes durante los 14 an˜os
(941 biopsias) en 5 hospitales de la comunidad autónoma. En 2008 se evaluó la situación
vital  y renal de los pacientes y se analizaron los factores asociados a dicha situación en
cada enfermedad.
Resultados: De las 941 biopsias, el 59% fueron de varones con una edad media de 48 ± 18 an˜os.
En  el momento de la biopsia la mediana de ﬁltrado glomerular (FG) era de 50,3 (25,5-76,3)
ml/min/1,73 m2 y la de proteinuria de 3,4 (1,5-6,4) g al día. La enfermedad más frecuente fue
la  nefropatía lúpica, seguida de la glomeruloesclerosis focal y segmentaria, y de la mem-
branosa. El mejor pronóstico renal durante el seguimiento (media 7,3 ± 4,8 an˜os) fue el de
la  nefropatía lúpica y la nefropatía por cambios mínimos; la glomeruloesclerosis focal y
segmentaria y las glomerulonefritis rápidamente progresivas de tipo 3 tuvieron el peor
pronóstico renal. Esta última, además, tuvo el peor pronóstico vital.
Conclusiones: GLOMANCHA demuestra el mal pronóstico de las glomerulonefritis rápida-
mente progresivas de tipo 3, a diferencia de la nefropatía por cambios mínimos y lúpica.
La  función renal es un predictor independiente de supervivencia renal y de mortalidad en
nuestra población.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Percutaneous biopsy is the test of choice for the diagnosis
of kidney diseases. Nephrologists make decisions regarding
treatment and prognosis by studying the biopsy’s histological
data.1
This technique is safe and relatively simple to perform.
Renal biopsy complications are very limited and when they
do occur they are mainly minor.2 Some centres even advocate
biopsies in an outpatient setting, without the need for hospital
admission.3 Furthermore, practically half of biopsied patients
have a potentially treatable disease that tends to include the
use of immunosuppressant drugs, thus requiring a certain
degree of speciﬁcity in the diagnosis due to the adverse effect
proﬁle of these treatments.4 Choosing suitable candidates for
biopsy is, therefore, a challenge for nephrologists because the
beneﬁts of early and treatable diagnosis outweigh the risks if
carried out correctly.
Nevertheless, there are no established criteria for perform-
ing renal biopsy; the criteria vary according to different centres
or countries.1 In general, nephrotic syndrome, nephriticby-nc-nd/4.0/).
syndrome and acute renal failure tend to be main indications
for performing a biopsy.5–7
Spain’s largest histopathological data collection is the
Spanish Registry of Glomerulonephritis sponsored by the
Spanish Society of Nephrology, which has recorded more  than
22,000 biopsies to date.8,9 In the region of Castilla-La Mancha,
all the biopsies performed between 1994 and 2008 at hospi-
tals in Albacete, Ciudad Real, Cuenca, Guadalajara and Toledo
have been recorded.
This study aims to explore the epidemiological and clin-
ical characteristics of biopsied patients with a diagnosis of
glomerulonephritis in Castilla-La Mancha (GLOMANCHA) and
to analyse renal survival and mortality during follow-up.
Methods
PatientsRegistry of patients who have undergone biopsy in the
Autonomous Community of Castilla-La Mancha between 1994
and 2008. Data have been provided by different hospitals from
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Table 1 – Baseline characteristics of the population
biopsied.
Gender (male) 59%
Age (years) 48 (18)a
Renal function (MDRD) (ml/min/1.73 m2)c 50.3 (25.5–76.3)b
Proteinuria (g/day)c 3.4 (1.5–6.4)
Histological diagnosis, n (%)
Lupus nephritis 204 (21.7)a
Focal segmental 179 (19.0)a
Membranous 177 (18.8)a
Rapidly progressive type III 155 (16.5)a
IgA 137 (14.6)a
Minimal change disease 89 (9.5)a
Follow-up (years) 7.3 (4.8)a
a Mean (standard deviation).
Table 2 shows the data collected from the different diseases
biopsied. There was male predominance in all the entities
309
33%
224
24%
Ciudad Real Albacete Toledo
217
23%
99
10%
92
10%n e f r o l o g i a. 2 0 
he community provinces (Albacete, Ciudad Real, Cuenca,
uadalajara and Toledo). Forms were sent that included epi-
emiological data (age and gender) and renal function data
glomerular ﬁltration rate [GFR] and proteinuria) at the time
f renal biopsy and at the cut-off date in 2008 (death, alive
nd requiring renal replacement therapy or alive with no need
or renal replacement therapy). Each centre presented its own
ndications for renal biopsy.
istological  diagnosis
he following histological diagnoses were collected in the reg-
stry:
 Minimal change disease.
 IgA nephropathy.
 Rapidly progressive type III glomerulonephritis (vasculitis).
 Membranous nephropathy.
 Lupus nephritis.
 Focal segmental glomerulosclerosis.
Other biopsied diseases were excluded from the anal-
sis (n = 103) due to the small number of cases recorded
acute glomerulonephritis, membranoproliferative glomeru-
onephritis types I, II and III, extracapillary types I and II
lomerulonephritis and others), as were paediatric patients
ho  underwent biopsy.
ollow-up
ollow-up was ended in 2008, when vital status (alive or dead)
nd renal status (on renal replacement therapy [RRT] or not)
ere recorded. We  checked for an association between the
ifferent factors collected (age, gender, proteinuria and renal
unction) and survival (renal and overall) and multivariate
odels were carried out adjusted according to these fac-
ors. Proteinuria was analysed dichotomously according to the
edian for each disease.
tatistical  analysis
he variables are expressed as mean (standard deviation)
r median (interquartile interval) according to their distri-
ution. The Student’s t-test or Chi-squared test were used
or parametric variables and the Mann–Whitney test for non-
arametric variables. Overall and renal survival studies were
erformed using univariate and multivariate Cox regression
djusted according to the variables studied (age, gender, GFR
nd proteinuria). With an aim to show clinically signiﬁcant
redictive parameters in this study, the gender and GFR
ariables were treated as continuous variables and median
roteinuria was taken for each of the diseases studied. More-
ver, renal and overall survival curves were performed for the
ifferent diseases using the Kaplan–Meier estimator. A p-value
0.05 was considered to be signiﬁcant. All the analyses were
arried out using SPSS v18.0 (SPSS Inc., Chicago, IL, USA).b Median (interquartile range).
c At renal biopsy.
Results
Baseline  characteristics
Of the 941 biopsies recorded, 555 (59%) were men, with a
mean age of 48 ± 18 years. Median GFR estimated by MDRD
at the time of biopsy was 50.3 (25.5–76.3) ml/min/1.73 m2,
with a median proteinuria of 3.4 (1.5–6.4) g per day. The
most common diseases were lupus nephritis, focal segmental
glomerulosclerosis and membranous nephropathy. The rest
of the data is shown in Table 1. The distribution according to
centre is shown in Fig. 1.
Characteristics  of  each  histological  groupCuenca Guadalajara
Fig. 1 – Distribution of biopsies by centre.
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Table 2 – Baseline characteristics of the patients according to histological diagnosis.
MCD FSGS MN IgA RPGN type III LN
Gender (male) 56.2% 70.9% 59.3% 81.9% 55.5% 19.4%
Age (years)a 46 (20) 48 (16) 52 (16) 42 (15) 63 (13) 34 (15)
Renal function
(MDRD)
(ml/min/1.73 m2)b,c
75.3 (50.5–96.4) 45.1 (29.3–63.1) 67.1 (41.5–83.6) 48.1 (28.5–73.05) 13.6 (7.6–21.55) 65.9 (46.9–85.3)
Proteinuria (g/day)b,c 7.5 (5.0–11.2) 3.0 (1.7–5.5) 7.1 (4.9–11.4) 2.0 (1.1–3.7) 1.5 (0.8–2.5) 2.8 (1.2–4.9)
MCD: minimal change disease; RPGN type III: rapidly progressive glomerulonephritis type III; FSGS: focal segmental glomerulosclerosis; IgA:
IgA nephropathy; LN: lupus nephritis; MN: membranous nephritis.
a Mean (standard deviation).
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Fig. 2 – Renal survival curve of the different diseases
biopsied.
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IgA Focal segmental RPGN type IIIb Median (interquartile range).
c At renal biopsy.
– the most striking was IgA glomerulonephritis – except for
lupus nephritis (19.4% of the total), in which more women
were diagnosed. In terms of age of presentation, lupus nephri-
tis affected patients at the youngest age (34 ± 15 years) in
contrast to rapidly progressive glomerulonephritis type III
(63 ± 13 years). Data on renal function and proteinuria vary
according to the different diseases studied. Minimal change
disease and membranous nephropathy present normal renal
function medians (75.3 and 67.1 ml/min/m2, respectively) with
proteinuria greater than 7 g per day. Meanwhile, at the time
of biopsy, rapidly progressive glomerulonephritis type III pre-
sented a very deteriorated GFR (13.6; 7.6–21.55 ml/min/1.73 m2)
with less proteinuria than the other diseases (1.5; 0.8–2.5 g per
day).
Follow-up
During follow-up (7.3 ± 4.8 years), 146 patients died (15.5%); 74
prior to starting RRT (7.8%) and 72 (7.6%) who were already part
of the programme. A total of 53 patients were on dialysis at the
end of follow-up (5.6%), 74 had received a kidney transplant
(7.8%) and 609 (64.7%) were alive and had not required RRT.
Fifty-nine (59) patients were lost to follow-up (6.2%).
Factors  associated  with  renal  survival
A total of 199 patients (10.5%) required RRT. Fig. 2 shows
the renal survival curves for the different diseases. Of these,
IgA glomerulonephritis, focal segmental glomerulosclerosis
and rapidly progressive glomerulonephritis type III were asso-
ciated with the worst prognosis. Overall, proteinuria and a
decrease in GFR were independent predictive factors for worse
renal survival in a model adjusted for age and gender (Table 3).
In terms of the diseases individually, deterioration in GFR was
associated with worse renal prognosis in all the diseases. How-
ever, proteinuria was only an independent predictive factor in
IgA glomerulonephritis (Table 3). Taking proteinuria continu-
ously, the results overlapped (data not shown).
Mortality-related  factorsA total of 146 patients (15.5%) died during follow-up. Fig. 3
shows the survival curves for the different diseases. Rapidly
progressive glomerulonephritis type III presented the worst
vital prognosis. Overall, a worse GFR and age (data not shown
Fig. 3 – Overall survival curve of the different diseases
biopsied.
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Table 3 – Univariate and multivariate Cox regression for renal and overall survival of the categories with a worse
prognosis.
Unadjusted renal survival Adjusted renal survivala Unadjusted overall survival Adjusted overall survivala
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Focal segmental glomerulosclerosis (n = 179)
Initial MDRD 0.96 (0.95–0.97) <0.01 0.96 (0.95–0.97) <0.01 0.96 (0.94–0.98) <0.01 0.98 (0.96–1.00) 0.09
Proteinuria > 3 g/dayb 1.49 (0.91–2.45) 0.12 1.44 (0.86–2.43) 0.16 1.69 (0.78–3.67) 0.17 1.38 (0.62–3.06) 0.42
Membranous nephropathy (n = 177)
Initial MDRD 0.95 (0.94–0.97) <0.01 0.96 (0.94–0.98) <0.01 0.96 (0.95–0.98) <0.01 0.98 (0.96–0.99) 0.02
Proteinuria > 7.1 g/dayb 1.01 (0.41–2.52) 0.97 0.70 (0.27–1.78) 0.46 2.12 (1.00–4.49) 0.05 1.51 (0.70–3.29) 0.29
IgA nephropathy (n = 137)
Initial MDRD 0.95 (0.94–0.96) <0.01 0.94 (0.93–0.96) <0.01 0.97 (0.93–0.98) <0.01 0.98 (0.95–1.01) 0.09
Proteinuria > 2.0 g/dayb 2.28 (1.29–4.01) <0.01 2.91 (1.61–5.25) <0.01 1.21 (0.48–3.06) 0.68 0.93 (0.32–2.67) 0.89
Rapidly progressive GN type III (n = 155)
Initial MDRD 0.91 (0.87–0.96) <0.01 0.91 (0.87–0.96) <0.01 0.96 (0.92–0.98) <0.01 0.97 (0.94–1.00) 0.08
Proteinuria > 1.5 g/dayb 1.28 (0.65–2.52) 0.47 1.15 (0.58–2.29) 0.68 1.02 (0.58–1.78) 0.94 1.07 (0.61–1.90) 0.80
Complete sample (n = 941)
Initial MDRD 0.95 (0.94–0.96) <0.01 0.96 (0.95–0.96) <0.01 0.96 (0.95–0.96) <0.01 0.97 (0.97–0.98) <0.01
Proteinuria > 3.4 g/dayb 1.04 (0.77–1.39) 0.79 1.49 (1.11–2.02) <0.01 0.98 (0.71–1.37) 0.93 1.15 (0.81–1.64) 0.43
GN: glomerulonephritis; HR (95% CI): hazard ratio (95% conﬁdence interval).
a Each disease has been analysed separately using univariate Cox regression and adjusted for age and gender. The initial glomerular ﬁltration
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n the table, HR 1.07; 95% CI: 1.05–1.08; p < 0.001) were inde-
endently associated with mortality in a model adjusted for
roteinuria and gender (Table 3). By analysing each disease
eparately, we  found that age was the most important inde-
endent predictive factor for mortality in all diseases (data
ot shown) and only deterioration in GFR predicted mortal-
ty in membranous nephropathy, maintaining a trend in the
ther diseases (Table 3).
iscussion
he Castilla-La Mancha biopsy registry presents extended
ollow-up (more than 7 years) and shows that patients under-
oing this procedure are predominately men, with a mean
ge of 48 years, mildly decreased renal function and protein-
ria greater than 3 g per day. The most common histological
iagnoses were lupus nephritis followed by focal segmental
lomerulosclerosis and membranous nephropathy. Although
hese data may initially draw attention, the results must be put
nto context, as each centre has their own indications for renal
iopsy; they do not reﬂect the total incidence of these diseases,
ut rather only those which are diagnosed histopathologi-
ally. Renal survival is excellent in lupus nephropathy and
n minimal change disease, unlike focal segmental glomeru-
osclerosis and rapidly progressive glomerulonephritis type
II. The latter, moreover, has the worst vital prognosis.
ll these data are consistent with the registries published
reviously.10,11
In terms of incidence, IgA nephropathy has always
emained at the head of the Spanish Registry of Glomeru-
onephritis, followed by lupus nephritis. According to
010–2013 data, focal segmental glomerulosclerosis and
embranous nephropathy were in third and fourth placethan the median for each disease.
respectively. This difference with our series is probably due to
the lack of biopsies in the IgA group, if they do not present poor
prognosis data and if clinical manifestations are suggestive of
this disease.
Regarding the diseases with poor renal prognosis, it was
interesting that in our sample GFR at the time of biopsy was
the predictor for renal survival, and not proteinuria. Only
in IgA nephropathy, proteinuria greater than 2 g multiplied
the risk for starting RRT by 2.9. In a study that included 141
patients, the Spanish Society of Nephrology Glomerular Dis-
ease Study Group (GLOSEN) conﬁrmed the excellent prognosis
for patients with IgA nephropathy and minimum or null pro-
teinuria in the long term.12
Rapidly progressive glomerulonephritis type III, which
presents the worst prognosis of the diseases studied, has a
severely decreased GFR (MDRD 13.6 ml/min/1.73 m2), with a
mean age greater than the other diseases (63 years) at the
time of biopsy. These 2 situations are consistent with data
recently published by the SEN (Spanish Society of Nephrol-
ogy) registry and both (GFR and age) are responsible for its poor
prognosis.8
Membranous nephropathy is, together with minimal
change disease, the disease with the most proteinuria at the
time of biopsy (more than 7 g per day). Furthermore, both
present a GFR greater than 60 ml/min/1.73 m2. Overall and
renal survival are good at 15 years follow-up (greater than
80%). Nevertheless, membranous nephropathy is probably
under-diagnosed. More  and more  authors are advocating for
performing biopsy in diabetic patients with proteinuria, as this
is often erroneously attributed to diabetic nephropathy.13 In a
recent study published by Soleymanian et al., renal biopsy was
performed in 46 diabetic patients with proteinuria, haema-
turia or impaired kidney function and only 34.8% had pure
diabetic nephropathy.14
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Clinicopathological and outcome analysis of adult lupus
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At the time of renal biopsy, the patients with focal seg-
mental glomerulosclerosis presented deterioration of renal
function with GFR estimated at 45.1 ml/min/1.73 m2 and a
median proteinuria of 3 g per day. These data are consistent
with other registries published in the work of Kwon et al.,
which included 111 Korean adults.15 There was a male pre-
dominance (70%) in the sample. Renal function marked the
patients’ prognosis, whose renal survival was poor. As in our
study, the prognosis factors in the Korean study were renal
function and age, but also proteinuria. This is because the
ﬁnal variable of their study was combined, including increased
serum creatinine or start of RRT, unlike our study in which we
only considered the latter. Moreover, since D’Agati proposed
a classiﬁcation of histological variants in 2003, several stud-
ies have aimed to assess renal prognosis in each of these.16
Although there is no clear consensus on whether histological
type is a prognostic factor, the collapsing variant seems to be
the most aggressive.17,18
In terms of lupus nephritis, previously published data is
conﬁrmed regarding the involvement of mainly young women
and proteinuria less than 2 g per day. For this disease, mem-
branous nephritis has the best renal prognosis compared to
the diffuse proliferative variant.19,20
Our study is not exempt of limitations, such as the small
amount of data collected from the patients (to facilitate the
delivery from the collaborating centres) or its retrospective
nature. Moreover, it should be highlighted that only baseline
analytical patient data were recorded, which also involves cer-
tain limitations. Furthermore, we  do not have the treatment
data for the patients biopsied and there may be a certain
degree of heterogeneity as we  looked at diseases from differ-
ent centres. Nevertheless, the large sample size and follow-up
period grant validity to the results presented.
In conclusion, the Castilla-La Mancha Registry of Glomeru-
lonephritis shows the poor prognosis of rapidly progressive
glomerulonephritis type III, unlike minimal change disease
and lupus nephritis. Renal function is an independent pre-
dictor of renal survival and mortality in our population.
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